JSR Life Sciences Expands Its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland
JSR Life Sciences, LLC today announced that it is increasing its European footprint with a newly expanded, state-of-the-art facility that will co-locate primary European operations for its affiliate companies KBI Biopharma and Selexis SA. The two companies combined will occupy 8,700 square meters in the Stellar 32 campus within Geneva’s ZIPLO (Industrial Zone Plan-les-Ouates). KBI Biopharma’s expanded facility will enable the Company to offer clinical cGMP biologics bulk drug substance manufacturing for European clients. Selexis’ new workspaces will allow the Company to meet the increasing demand for its highly specialized mammalian cell line development technologies and services. Together, the companies anticipate creating more than 250 new highly technical jobs in the new facilities.
JSR Life Sciences invested in the co-located operations to help meet the needs of its European client base. This arrangement will facilitate additional options for clients to leverage efficiencies for integrating Selexis’ SUREtechnology TM protein expression platform with KBI’s advanced process and analytical development tools.
“JSR Life Sciences is proud to have best-in-class companies focused on translating customers’ ideas into novel biologics that are improving patients’ lives worldwide,” said Tim Lowery, President of JSR Life Sciences. “This strategic investment in our European operations creates new options by linking the core strengths of our affiliates, increases efficiencies, and ultimately accelerates our customers’ ability to bring innovative life science products into the marketplace. In addition, KBI and Selexis will benefit from the extensive biopharma industrial base, advanced technical resources, and specialized education offerings in this region.”
KBI Biopharma’s new 5,600-square-meter biologic bulk drug substance manufacturing facility is scheduled to be operational by mid-2022 and will create more than 200 technical positions in development, operations, and quality assurance. From this facility, KBI will supply customers with cGMP bulk drug substance to meet their clinical trial requirements. The expanded capabilities include two 2,000L single-use cGMP manufacturing trains with process development and analytical testing labs on site. cGMP quality control testing for release and in-process testing will be performed on-site in the new Geneva facility, while cGMP testing of drug substance and drug product stability will remain at the KBI Biopharma BVBA laboratories in Leuven, Belgium.
Selexis’ Geneva footprint will increase by 200% and is scheduled to be operational by mid-2021. The new space will include laboratory, office, health/wellness, and employee common spaces. Throughout the expansion, Selexis has maintained its commitment to Corporate Social Responsibility (CSR) through investing in a Minergie-certified building (a Swiss building standard aimed at construction with above-average demands on quality, comfort, and energy) with an energy balance 20% better than Swiss recommendations for energy resource and conservation1. Floorplans support the unique technical needs of Selexis cell line workflows, including department-wide segregation and state-of-the-art monitoring systems. In addition to new standard cell line development suites, the new facility will also include two separate cell culture suites to accommodate quarantined client-specific cell lines or client-dedicated cell line spaces.
“This expansion is a cornerstone of our European growth strategy, which builds on Selexis’ innovative cell line technologies and KBI’s strong expertise in biologics manufacturing to meet the needs of our clients’ clinical trial requirements. The new facility allows us to increase engagement with a broader client base with whom we can partner more effectively due to our local presence,” said Dirk Lange, President and CEO of KBI Biopharma and CEO of Selexis SA. “As science progresses, research and treatments become increasingly complex and sophisticated, and we are fully prepared to keep pace with our clients’ needs by providing the latest life science discovery and development technology. Furthermore, by co-locating these operations, the synergies for rapid cell line and process development and introduction to manufacturing will be tremendous, which we see as a true advantage for our client base.”
The Stellar 32 facility remains in the center of highly diversified industrial companies in Geneva. It provides easy access for clients and employees, located close to the A1 Motorway, Geneva Airport, and public transportation including buses, trams, and multiple railways. The location will also provide convenient access to a three-star hotel as well as a restaurant and fitness center.
About JSR Life Sciences, LLC
JSR Life Sciences, LLC is committed to the advancement of human health worldwide as a strategic partner to companies that discover, develop, and deliver products to treat disease and improve the quality of life for patients. Based in Sunnyvale, California, JSR Life Sciences operates a network of manufacturing facilities, R&D labs and sales offices. The JSR Life Sciences family of companies includes Crown Bioscience, KBI Biopharma, Inc., Medical & Biological Laboratories Co., LTD., Selexis SA and other affiliates throughout Europe and the Asia-Pacific region.
About KBI Biopharma, Inc.
KBI Biopharma is an award-winning biopharmaceutical contract services organization providing fully integrated, accelerated drug development and biomanufacturing services to pharmaceutical and biotechnology companies globally. With each of our 300+ client partners, we have worked closely to personalize and rapidly accelerate their drug development programs. Built upon a foundation of world-class analytical capabilities, we deliver efficient process development and clinical and commercial cGMP manufacturing services for mammalian, microbial, and cell therapy programs. We have locations in Durham and Research Triangle Park (NC), Boulder and Louisville (CO), The Woodlands (TX), Geneva, Switzerland, and Leuven, Belgium. More information is available at www.kbibiopharma.com.
About Selexis SA
Selexis SA, a JSR Life Sciences Company, is the global leader in cell line development with best-in-class modular technology and highly specialized solutions that enable the life sciences industry to rapidly discover, develop, and commercialize innovative medicines and vaccines. Our global partners are utilizing Selexis technologies to advance more than 130 drug products in clinical development and the manufacture of eight commercial products. As part of a comprehensive drug development process, the Company’s technologies shorten development timelines and reduce manufacturing risks. More information is available at www.selexis.com.
1 The “Model Regulations of the Cantons in the Energy Sector” (MuKEn) is the “overall package” of energy law model regulations in the building sector that the cantons have jointly developed based on their implementation experience.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201020005340/en/
Contact information
Media Inquiries
Mike Beyer
Sam Brown Inc.
+1 312-961-2502
mikebeyer@sambrown.com
Company Inquiries
Missy Bindseil
JSR North America Holdings, Inc.
JSR Life Sciences, LLC
+1 830-237-9527
mbindseil@jsr-nahq.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku opens Rigaku Technology Center Taiwan20.10.2025 18:00:00 EEST | Press release
Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”) hereby announces the establishment of Rigaku Technology Taiwan Co., Ltd. (hereinafter “RTTW”), a new group company in Taiwan, in 2025. A facility within RTTW, Rigaku Technology Center Taiwan (hereinafter RTC-TW), began full-scale operation in October 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251020130286/en/ Rigaku Technology Taiwan Co., Ltd., located in Tai Yuen Hi-Tech Industry Park RTTW will assume duties formerly managed by Rigaku Taiwan Branch (RCTW), established in 2024. As Rigaku’s base of operations in Chinese-speaking East Asia, RTTW aims to strengthen customer support and advance sustainable growth in the region. RTC-TW will serve as an engineering base for advancing R&D, customer support, and joint development. The facility will include a clean room that replicates actual production environments, along w
InterSystems and Google Cloud Integrate InterSystems HealthShare with Google Cloud’s Healthcare API20.10.2025 17:00:00 EEST | Press release
InterSystems, a creative data technology provider managing over one billion health records worldwide, today announced a new partnership that integrates InterSystems HealthShare with Google Cloud. Announced at HLTH, this collaboration aims to deliver a scalable, real-time, harmonized data foundation for generative and agentic AI applications. The partnership addresses one of the most pressing challenges in healthcare IT: fragmented and inconsistent data. By combining InterSystems expertise in data harmonization, identity resolution, and interoperability with Google Cloud’s broad suite of AI-enabled analytics and search capabilities and secure infrastructure, healthcare organizations can now unlock the full potential of AI with clean, unified, and actionable data on a proven, enterprise-grade cloud platform. “AI is transforming healthcare, but it can only succeed when it’s grounded in reliable, actionable data,” said Don Woodlock, head of Global Healthcare Solutions at InterSystems. “By
Wolters Kluwer supports SOCAR’s digital transformation journey with launch of Enablon Control of Work solution at Pirallahi Island upstream facility20.10.2025 16:30:00 EEST | Press release
Wolters Kluwer today announced that the State Oil Company of the Azerbaijan Republic (SOCAR) has successfully launched the Enablon Control of Work (CoW) solution at its first upstream oil gathering location in the Abşeronneft Oil and Gas Production Department (OGPD), located on Pirallahi Island. In line with its digital transformation efforts, the company shifts from manual, paper-based systems to fully integrated digital workflows for managing work permits, isolations, risk assessments, and safety protocols. As the fully state-owned enterprise responsible for oil and natural gas production from both onshore and offshore fields in the Azerbaijani sector of the Caspian Sea, SOCAR plays a vital role in the nation’s energy infrastructure. It operates Azerbaijan’s only oil refinery, a gas processing plant, and oversees several strategic oil and gas export pipelines. With the rollout of the Enablon CoW solution, SOCAR is strengthening its commitment to standardizing safety practices across
Lenovo Advances the AI-Enabled Workforce with Agentic AI: Trusted, Proven, and Ready to Deliver ROI20.10.2025 16:00:00 EEST | Press release
As enterprises race to capture value from AI, Lenovo today unveiled new agentic AI capabilities as the centerpiece of its AI-Enabled Workforce portfolio, a complete suite of devices, services, and lifecycle solutions that turn AI investments into measurable business value. According to IDC, enterprises are already realizing nearly $4 in return for every $1 invested in generative AI, and by 2027 agentic AI is expected to double workforce productivity worldwide1 – evidence that organizations are moving from AI experimentation to tangible results. This marks a turning point where enterprises are shifting from piloting AI to embedding intelligent automation across their workforces, and Lenovo is helping lead this transformation. With Lenovo’s agentic AI capabilities, organizations can deploy digital agents that work independently or alongside employees to manage workflows, automate tasks, and support smarter decisions within trusted security guardrails. Backed by Lenovo’s AI infrastructure
TagEnergy Selects Sitetracker to Accelerate Renewable Energy Growth20.10.2025 16:00:00 EEST | Press release
Sitetracker, the global leader in complete Asset Lifecycle Management for critical infrastructure, today announced that TagEnergy, a fast-growing renewable energy producer, has selected Sitetracker to standardize operations and scale its portfolio across multiple markets. The move underscores TagEnergy’s commitment to delivering clean energy projects more efficiently while maintaining the highest standards of quality and transparency. TagEnergy develops and operates wind, solar, and battery storage projects across Europe, Japan and Australia, and is on track to double its size in the next three to four years. To support this growth, the company required a modern, flexible platform to unify processes across departments and countries, eliminate reliance on spreadsheets, and provide real-time visibility into project performance. By deploying Sitetracker, TagEnergy will: Get more done faster by eliminating manual tasks, standardizing workflows, and enabling teams to manage more projects wi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom